Quick Answer
Cullinan Therapeutics, Inc. reported Operating Income Loss of -$241.65 million for the year ending 2025.
- Cullinan Therapeutics, Inc. showed a decrease of -22.7% in Operating Income Loss from 2024 to 2025.
- This data is from Cullinan Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 10, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2020: -$5.54 million | Q2 2020: -$14.12 million | Q3 2020: -$11.50 million | Q1 2021: $1.37 million | Q2 2021: -$16.60 million | Q3 2021: -$18.38 million | Q1 2022: -$32.66 million | Q2 2022: $239.68 million | Q3 2022: -$29.77 million | Q1 2023: -$62.76 million | Q2 2023: -$37.61 million | Q3 2023: -$45.24 million | Q1 2024: -$42.99 million | Q2 2024: -$50.03 million | Q3 2024: -$48.86 million | Q1 2025: -$55.00 million | Q2 2025: -$75.80 million | Q3 2025: -$55.60 million.
- Over the full 6 years of available data (2020 to 2025), Cullinan Therapeutics, Inc.'s Operating Income Loss has declined by 300.5%.
- Historical annual values: Fiscal year 2025: -$241.65 million | Fiscal year 2024: -$196.92 million | Fiscal year 2023: -$191.09 million | Fiscal year 2022: $144.65 million | Fiscal year 2021: -$67.95 million | Fiscal year 2020: -$60.34 million.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: